Diagnostic: cobas EGFR (epidermal growth factor receptor) Mutation Test v2 (Roche Molecular)
Status: Approved as a blood-based companion diagnostic for osimertinib (Tagrisso, AstraZeneca) to provide an alternative way of identifying non-small cell lung cancer (NSCLC) patients with metastatic EGFR T790M mutation–positive NSCLC at disease progression
Significant Data:
- Defined EGFR mutations are detected using DNA isolated from formalin-fixed paraffin-embedded tumor tissue (FFPET) or